Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 2/2016

01-04-2016

The Role and Immunobiology of Eosinophils in the Respiratory System: a Comprehensive Review

Authors: Stephanie S. Eng, Magee L. DeFelice

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2016

Login to get access

Abstract

The eosinophil is a fully delineated granulocyte that disseminates throughout the bloodstream to end-organs after complete maturation in the bone marrow. While the presence of eosinophils is not uncommon even in healthy individuals, these granulocytes play a central role in inflammation and allergic processes. Normally appearing in smaller numbers, higher levels of eosinophils in the peripheral blood or certain tissues typically signal a pathologic process. Eosinophils confer a beneficial effect on the host by enhancing immunity against molds and viruses. However, tissue-specific elevation of eosinophils, particularly in the respiratory system, can cause a variety of short-term symptoms and may lead to long-term sequelae. Eosinophils often play a role in more commonly encountered disease processes, such as asthma and allergic responses in the upper respiratory tract. They are also integral in the pathology of less common diseases including eosinophilic pneumonia, allergic bronchopulmonary aspergillosis, hypersensitivity pneumonitis, and drug reaction with eosinophilia and systemic symptoms. They can be seen in neoplastic disorders or occupational exposures as well. The involvement of eosinophils in pulmonary disease processes can affect the method of diagnosis and the selection of treatment modalities. By analyzing the complex interaction between the eosinophil and its environment, which includes signaling molecules and tissues, different therapies have been discovered and created in order to target disease processes at a cellular level. Innovative treatments such as mepolizumab and benralizumab will be discussed. The purpose of this article is to further explore the topic of eosinophilic presence, activity, and pathology in the respiratory tract, as well as discuss current and future treatment options through a detailed literature review.
Literature
1.
Wardlaw AJ, Brightling C, Green R, Woltmann G, Pavord I (2000) Eosinophils in asthma and other allergic diseases. Br Med Bull 56:985–1003PubMedCrossRef
2.
3.
Adkinson NF, Bochner BS, Busse WW et al (2009) Middleton’s allergy: principles and practice, 7th edn. Mosby/Elsevier, Philadelphia
4.
Adkinson NF, Bochner BS, Burks AW et al (2014) Middleton’s allergy: principles and practice, 8th edn. Elsevier/Saunders, Philadelphia
5.
6.
7.
Lilly LM, Scopel M, Nelson MP, Burg AR, Dunaway CW, Steele C (2014) Eosinophil deficiency compromises lung defense against Aspergillus fumigatus. Infect Immun 82:1315–1325PubMedPubMedCentralCrossRef
8.
Wechsler ME (2007) Pulmonary eosinophilic syndromes. Immunol Allergy Clin N Am 27:477–492CrossRef
9.
Cottin V, Cordier JF (2012) Eosinophilic lung diseases. Immunol Allergy Clin N Am 32:557–586CrossRef
10.
Jeong YJ, Kim KI, Seo IJ et al (2007) Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview. Radiographics Rev Publ Radiol Soc North Am Inc 27:617–637, discussion 637-619
11.
Ying S, Meng Q, Zeibecoglou K et al (1999) Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. J Immunol 163:6321–6329PubMed
12.
Peterson MW, Monick M, Hunninghake GW (1987) Prognostic role of eosinophils in pulmonary fibrosis. Chest 92:51–56PubMedCrossRef
13.
Henderson WR, Chi EY, Klebanoff SJ (1980) Eosinophil peroxidase-induced mast cell secretion. J Exp Med 152:265–279PubMedCrossRef
14.
Dechatelet LR, Migler RA, Shirley PS, Bass DA, McCall CE (1978) Enzymes of oxidative metabolism in the human eosinophil. Proceedings of the Society for Experimental Biology and Medicine. Soc Exp Biol Med 158:537–541CrossRef
15.
Rudd RM, Haslam PL, Turner-Warwick M (1981) Cryptogenic fibrosing alveolitis. Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis 124:1–8PubMed
16.
Frigas E, Loegering DA, Gleich GJ (1980) Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium. Lab Investig J Tech Methods Pathol 42:35–43
17.
Davis WB, Fells GA, Sun XH, Gadek JE, Venet A, Crystal RG (1984) Eosinophil-mediated injury to lung parenchymal cells and interstitial matrix. A possible role for eosinophils in chronic inflammatory disorders of the lower respiratory tract. J Clin Investig 74:269–278PubMedPubMedCentralCrossRef
18.
Weller PF (2014) Approach to the patient with unexplained eosinophilia
19.
Daimon T, Johkoh T, Sumikawa H et al (2008) Acute eosinophilic pneumonia: thin-section CT findings in 29 patients. Eur J Radiol 65:462–467PubMedCrossRef
20.
21.
Rom WN, Weiden M, Garcia R et al (2002) Acute eosinophilic pneumonia in a New York City firefighter exposed to World Trade Center dust. Am J Respir Crit Care Med 166:797–800PubMedCrossRef
22.
Philit F, Etienne-Mastroianni B, Parrot A, Guerin C, Robert D, Cordier JF (2002) Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med 166:1235–1239PubMedCrossRef
23.
Rose DM, Hrncir DE (2013) Primary eosinophilic lung diseases. Allergy Asthma Proc Off J Reg State Allergy Soc 34:19–25CrossRef
24.
Janz DR, O’Neal HR Jr, Ely EW (2009) Acute eosinophilic pneumonia: a case report and review of the literature. Crit Care Med 37:1470–1474PubMedCrossRef
25.
26.
Carrington CB, Addington WW, Goff AM et al (1969) Chronic eosinophilic pneumonia. N Engl J Med 280:787–798PubMedCrossRef
27.
Ge Y, Han X, Liu X (2013) Chronic eosinophilic pneumonia: a case report and review of the literature. Open J Internal Med 3:121–125CrossRef
28.
29.
Okubo Y, Horie S, Hachiya T et al (1998) Predominant implication of IL-5 in acute eosinophilic pneumonia: comparison with chronic eosinophilic pneumonia. Int Arch Allergy Immunol 116:76–80PubMedCrossRef
30.
Jhun BW, Kim SJ, Kim K, Lee JE, Hong DJ (2014) Clinical implications of correlation between peripheral eosinophil count and serum levels of IL-5 and tryptase in acute eosinophilic pneumonia. Respir Med
31.
Obayashi Y, Yamadori I, Fujita J, Yoshinouchi T, Ueda N, Takahara J (1997) The role of neutrophils in the pathogenesis of idiopathic pulmonary fibrosis. Chest 112:1338–1343PubMedCrossRef
32.
Prasad R, Gupta N, Singh A, Gupta P (2015) Diagnosis of idiopathic pulmonary fibrosis: current issues. Intractable Rare Diseases Res 4:65–69CrossRef
33.
Iwai K, Mori T, Yamada N, Yamaguchi M, Hosoda Y (1994) Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med 150:670–675PubMedCrossRef
34.
Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G (2006) Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174:810–816PubMedCrossRef
35.
Kroegel C, Foerster M, Grahmann PR, Braun R (1998) Eosinophil priming and migration in idiopathic pulmonary fibrosis. Eur Respir J 11:999–1001PubMedCrossRef
36.
37.
Klion A (2009) Hypereosinophilic syndrome: current approach to diagnosis and treatment. Annu Rev Med 60:293–306PubMedCrossRef
38.
Ogbogu PU, Bochner BS, Butterfield JH et al (2009), Hypereosinophilic syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 124, 1319-1325
39.
Fernandez Perez ER, Olson AL, Frankel SK (2011) Eosinophilic lung diseases. Med Clin North Am 95:1163–1187PubMedCrossRef
40.
Mullarkey MF, Hill JS, Webb DR (1980) Allergic and nonallergic rhinitis: their characterization with attention to the meaning of nasal eosinophilia. J Allergy Clin Immunol 65:122–126PubMedCrossRef
41.
Bachert C (2004) Persistent rhinitis—allergic or nonallergic? Allergy 59(Suppl 76):11–15, discussion 15PubMedCrossRef
42.
Moneret-Vautrin DA, Hsieh V, Wayoff M, Guyot JL, Mouton C, Maria Y (1990) Nonallergic rhinitis with eosinophilia syndrome a precursor of the triad: nasal polyposis, intrinsic asthma, and intolerance to aspirin. Annals of allergy 64:513–518PubMed
43.
Leone C, Teodoro C, Pelucchi A et al (1997) Bronchial responsiveness and airway inflammation in patients with nonallergic rhinitis with eosinophilia syndrome. J Allergy Clin Immunol 100:775–780PubMedCrossRef
44.
Ellis AK, Keith PK (2006) Nonallergic rhinitis with eosinophilia syndrome. Current Allergy Asthma Rep 6:215–220CrossRef
45.
Fang CH, Mady LJ, Mirani NM, Baredes S, Eloy JA (2014) Sinonasal eosinophilic angiocentric fibrosis: a systematic review. Int Forum Allergy Rhinology 4:745–752CrossRef
46.
Nguyen DB, Alex JC, Calhoun B (2004) Eosinophilic angiocentric fibrosis in a patient with nasal obstruction. Ear Nose Throat J 83:183–184, 186PubMed
47.
Onder S, Sungur A (2004) Eosinophilic angiocentric fibrosis: an unusual entity of the sinonasal tract. Arch Pathol Lab Med 128:90–91PubMed
48.
Jain R, Robblee JV, O’Sullivan-Mejia E et al (2008) Sinonasal eosinophilic angiocentric fibrosis: a report of four cases and review of literature. Head Neck Pathol 2:309–315PubMedPubMedCentralCrossRef
49.
Lotvall J, Akdis CA, Bacharier LB et al (2011) Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 127:355–360PubMedCrossRef
50.
51.
National Asthma E, Prevention P (2007) Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 120:S94–S138CrossRef
52.
Keglowich L, Roth M, Philippova M et al (2013) Bronchial Smooth muscle cells of asthmatics promote angiogenesis through elevated secretion of CXC-Chemokines (ENA-78, GRO-alpha, and IL-8). PLoS One 8, e81494PubMedPubMedCentralCrossRef
53.
Agache I, Akdis C, Jutel M, Virchow JC (2012) Untangling asthma phenotypes and endotypes. Allergy 67:835–846PubMedCrossRef
54.
Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE (2004) Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 113:101–108PubMedCrossRef
55.
56.
Green RH, Brightling CE, McKenna S et al (2002) Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360:1715–1721PubMedCrossRef
57.
Al-Samri MT, Benedetti A, Prefontaine D et al (2010) Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samples. J Allergy Clin Immunol 125(1161–1163), e1164
58.
Wang F, He XY, Baines KJ et al (2011) Different inflammatory phenotypes in adults and children with acute asthma. Eur Respir J 38:567–574PubMedCrossRef
59.
Walford HH, Doherty TA (2014) Diagnosis and management of eosinophilic asthma: a US perspective. J Asthma Allergy 7:53–65PubMedPubMedCentral
60.
61.
Campo P, Rodriguez F, Sanchez-Garcia S et al (2013) Phenotypes and endotypes of uncontrolled severe asthma: new treatments. J Investig Allergol Clin Immunol 23:76–88, quiz 71 p follow 88PubMed
62.
Xie M, Wenzel SE (2013) A global perspective in asthma: from phenotype to endotype. Chin Med J 126:166–174PubMed
63.
Wenzel S (2012) Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy J Br Soc Allergy Clin Immunol 42:650–658CrossRef
64.
Hamelmann E, Gelfand EW (2001) IL-5-induced airway eosinophilia—the key to asthma? Immunol Rev 179:182–191PubMedCrossRef
65.
Pace E, Ferraro M, Siena L et al (2008) Cigarette smoke increases Toll-like receptor 4 and modifies lipopolysaccharide-mediated responses in airway epithelial cells. Immunology 124:401–411PubMedPubMedCentralCrossRef
66.
Monick MM, Yarovinsky TO, Powers LS et al (2003) Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem 278:53035–53044PubMedCrossRef
67.
Galowitz S, Chang C (2014) Immunobiology of Critical Pediatric Asthma. Clin Rev Allergy Immunol
68.
Muzio M, Polentarutti N, Bosisio D, Manoj Kumar PP, Mantovani A (2000) Toll-like receptor family and signalling pathway. Biochem Soc Trans 28:563–566PubMedCrossRef
69.
Dabbagh K, Dahl ME, Stepick-Biek P, Lewis DB (2002) Toll-like receptor 4 is required for optimal development of Th2 immune responses: role of dendritic cells. J Immunol 168:4524–4530PubMedCrossRef
70.
Saenz SA, Siracusa MC, Perrigoue JG et al (2010) IL25 elicits a multipotent progenitor cell population that promotes T(H)2 cytokine responses. Nature 464:1362–1366PubMedPubMedCentralCrossRef
71.
72.
Fort MM, Cheung J, Yen D et al (2001) IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15:985–995PubMedCrossRef
73.
Schneider E, Petit-Bertron AF, Bricard R et al (2009) IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. J Immunol 183:3591–3597PubMedCrossRef
74.
Zhou B, Comeau MR, De Smedt T et al (2005) Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol 6:1047–1053PubMedCrossRef
75.
Fang C, Siew LQ, Corrigan CJ, Ying S (2010) The role of thymic stromal lymphopoietin in allergic inflammation and chronic obstructive pulmonary disease. Arch Immunol Ther Exp 58:81–90CrossRef
76.
Trivedi SG, Lloyd CM (2007) Eosinophils in the pathogenesis of allergic airways disease. Cell Mol Life Sci CMLS 64:1269–1289PubMedCrossRef
77.
Jeffery PK (2000) Comparison of the structural and inflammatory features of COPD and asthma. Giles F Filley Lect Chest 117:251S–260S
78.
Qiu Y, Zhu J, Bandi V, Guntupalli KK, Jeffery PK (2007) Bronchial mucosal inflammation and upregulation of CXC chemoattractants and receptors in severe exacerbations of asthma. Thorax 62:475–482PubMedPubMedCentralCrossRef
79.
Fahy JV, Kim KW, Liu J, Boushey HA (1995) Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 95:843–852PubMedCrossRef
80.
Sur S, Crotty TB, Kephart GM et al (1993) Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis 148:713–719PubMedCrossRef
81.
Qiu Y, Zhu J, Bandi V et al (2003) Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 168:968–975PubMedCrossRef
82.
Imaizumi T, Albertine KH, Jicha DL, McIntyre TM, Prescott SM, Zimmerman GA (1997) Human endothelial cells synthesize ENA-78: relationship to IL-8 and to signaling of PMN adhesion. Am J Respir Cell Mol Biol 17:181–192PubMedCrossRef
83.
Wuyts A, Proost P, Lenaerts JP, Ben-Baruch A, Van Damme J, Wang JM (1998) Differential usage of the CXC chemokine receptors 1 and 2 by interleukin-8, granulocyte chemotactic protein-2 and epithelial-cell-derived neutrophil attractant-78. Eur J Biochem FEBS 255:67–73CrossRef
84.
Moore WC, Meyers DA, Wenzel SE et al (2010) Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 181:315–323PubMedPubMedCentralCrossRef
85.
Fitzpatrick AM, Teague WG, Meyers DA et al (2011) Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the national institutes of health/national heart, lung, and blood institute severe asthma research program. J Allergy Clin Immunol 127:382–389, e381-313PubMedPubMedCentralCrossRef
86.
Jarjour NN, Erzurum SC, Bleecker ER et al (2012) Severe asthma: lessons learned from the national heart, lung, and blood institute severe asthma research program. Am J Respir Crit Care Med 185:356–362PubMedPubMedCentralCrossRef
87.
Bossley CJ, Fleming L, Gupta A et al (2012) Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. J Allergy Clin Immunol 129:974–982, e913 PubMedPubMedCentralCrossRef
88.
Silkoff PE, Lent AM, Busacker AA et al (2005) Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. J Allergy Clin Immunol 116:1249–1255PubMedCrossRef
89.
Saglani S, Lloyd CM (2014) Eosinophils in the pathogenesis of paediatric severe asthma. Curr Opin Allergy Clin Immunol 14:143–148PubMedCrossRef
90.
Lemiere C, Ernst P, Olivenstein R et al (2006) Airway inflammation assessed by invasive and noninvasive means in severe asthma: eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol 118:1033–1039PubMedCrossRef
91.
Saglani S, Malmstrom K, Pelkonen AS et al (2005) Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction. Am J Respir Crit Care Med 171:722–727PubMedCrossRef
92.
Marguet C, Bocquel N, Benichou J et al (2008) Neutrophil but not eosinophil inflammation is related to the severity of a first acute epidemic bronchiolitis in young infants. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol 19:157–165CrossRef
93.
de Blic J, Tillie-Leblond I, Tonnel AB, Jaubert F, Scheinmann P, Gosset P (2004) Difficult asthma in children: an analysis of airway inflammation. J Allergy Clin Immunol 113:94–100PubMedCrossRef
94.
95.
96.
Stern DA, Morgan WJ, Halonen M, Wright AL, Martinez FD (2008) Wheezing and bronchial hyper-responsiveness in early childhood as predictors of newly diagnosed asthma in early adulthood: a longitudinal birth-cohort study. Lancet 372:1058–1064PubMedPubMedCentralCrossRef
97.
Gibson PG, Simpson JL, Saltos N (2001) Heterogeneity of airway inflammation in persistent asthma : evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 119:1329–1336PubMedCrossRef
98.
Gibson PG (2009) Inflammatory phenotypes in adult asthma: clinical applications. Clin Respir J 3:198–206PubMedCrossRef
99.
Jenkins HA, Cherniack R, Szefler SJ, Covar R, Gelfand EW, Spahn JD (2003) A comparison of the clinical characteristics of children and adults with severe asthma. Chest 124:1318–1324PubMedCrossRef
100.
Nizankowska E, Soja J, Pinis G et al (1995) Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur Respir J 8:1091–1099PubMedCrossRef
101.
Presta LG, Lahr SJ, Shields RL et al (1993) Humanization of an antibody directed against IgE. J Immunol 151:2623–2632PubMed
102.
Schulman ES (2001) Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med 164:S6–S11PubMedCrossRef
103.
Erin EM, Leaker BR, Nicholson GC et al (2006) The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 174:753–762PubMedCrossRef
104.
Gauvreau GM, Pageau R, Seguin R et al (2011) Dose-response effects of TPI ASM8 in asthmatics after allergen. Allergy 66:1242–1248PubMedCrossRef
105.
Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG (2008) Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 177:148–155PubMedCrossRef
106.
Ortega HG, Liu MC, Pavord ID et al (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371:1198–1207PubMedCrossRef
107.
Bel EH, Wenzel SE, Thompson PJ et al (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371:1189–1197PubMedCrossRef
108.
Laviolette M, Gossage DL, Gauvreau G et al (2013) Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 132(1086–1096), e1085
109.
Castro M, Wenzel SE, Bleecker ER et al. (2014) Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med
110.
Fitzpatrick AM, Gaston BM, Erzurum SC, Teague WG, National Institutes of Health/National Heart and P. Blood Institute Severe Asthma Research (2006) Features of severe asthma in school-age children: atopy and increased exhaled nitric oxide. J Allergy Clin Immunol 118:1218–1225PubMedPubMedCentralCrossRef
111.
Covar RA, Spahn JD, Martin RJ et al (2004) Safety and application of induced sputum analysis in childhood asthma. J Allergy Clin Immunol 114:575–582PubMedCrossRef
112.
Wedes SH, Wu W, Comhair SA et al (2011) Urinary bromotyrosine measures asthma control and predicts asthma exacerbations in children. J Pediatr 159(248–255), e241
113.
Selman M (2004) Hypersensitivity pneumonitis: a multifaceted deceiving disorder. Clin Chest Med 25(531–547):vi
114.
115.
Monkare S, Ikonen M, Haahtela T (1985) Radiologic findings in farmer’s lung. Prognosis Correlation Lung Funct Chest 87:460–466
116.
Cormier Y, Belanger J, LeBlanc P, Laviolette M (1986) Bronchoalveolar lavage in farmers’ lung disease: diagnostic and physiological significance. Br J Ind Med 43:401–405PubMedPubMedCentral
117.
Lacasse Y, Selman M, Costabel U et al (2003) Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med 168:952–958PubMedCrossRef
118.
Monkare S (1983) Influence of corticosteroid treatment on the course of farmer’s lung. Eur J Respir Dis 64:283–293PubMed
119.
Bochenek G, Nizankowska-Mogilnicka E (2013) Aspirin-exacerbated respiratory disease: clinical disease and diagnosis. Immunol Allergy Clin N Am 33:147–161CrossRef
120.
Burnett T, Katial R, Alam R (2013) Mechanisms of aspirin desensitization. Immunol Allergy Clin N Am 33:223–236CrossRef
121.
Choi JH, Kim MA, Park HS (2014) An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease. Curr Opin Allergy Clin Immunol 14:1–6PubMedCrossRef
122.
Saltzstein SL, Ackerman LV (1959) Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically pathologically malignant lymphomas. Cancer 12:164–182PubMedCrossRef
123.
Camous X, Calbo S, Picard D, Musette P (2012) Drug Reaction with eosinophilia and systemic symptoms: an update on pathogenesis. Curr Opin Immunol 24:730–735PubMedCrossRef
124.
Bocquet H, Bagot M, Roujeau JC (1996) Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutaneous Med Surg 15:250–257CrossRef
125.
Tetart F, Picard D, Janela B, Joly P, Musette P (2013) Prolonged Evolution of Drug Reaction With Eosinophilia and Systemic Symptoms: Clinical, Virologic, and Biological Features. JAMA Dermatol
126.
Peyriere H, Dereure O, Breton H et al (2006) Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatology 155:422–428CrossRef
127.
Favrolt N, Bonniaud P, Collet E et al (2007) Severe drug rash with eosinophilia and systemic symptoms after treatment with minocycline. Rev Mal Respir 24:892–895PubMedCrossRef
128.
Husain Z, Reddy BY, Schwartz RA (2013) DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol 68:693, e691-614; quiz 706-698PubMedCrossRef
129.
Kano Y, Shiohara T (2009) The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin N Am 29:481–501CrossRef
130.
Tohyama M, Hashimoto K, Yasukawa M et al (2007) Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol 157:934–940PubMedCrossRef
131.
Heiner DC, Sears JW, Kniker WT (1962) Multiple precipitins to cow’s milk in chronic respiratory disease. A syndrome including poor growth, gastrointestinal symptoms, evidence of allergy, iron deficiency anemia, and pulmonary hemosiderosis. Am J Dis Child 103:634–654PubMedCrossRef
132.
Moissidis I, Chaidaroon D, Vichyanond P, Bahna SL (2005) Milk-induced pulmonary disease in infants (Heiner syndrome). Pediatric Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol 16:545–552CrossRef
133.
134.
Lummus ZL, Wisnewski AV, Bernstein DI (2011) Pathogenesis and disease mechanisms of occupational asthma. Immunol Allergy Clin N Am 31(699–716):vi
135.
Malo JL, Vandenplas O (2011) Definitions and classification of work-related asthma. Immunol Allergy Clin N Am 31:645–662, vCrossRef
136.
Enriquez A, Fernandez C, Jimenez A, Seoane E, Alcorta AR, Rodriguez J (2011) Occupational asthma induced by Mucor species contaminating esparto fibers. J Investig Allergol Clin Immunol 21:251–252PubMed
137.
Agarwal R, Chakrabarti A, Shah A et al (2013) Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy J Br Soc Allergy Clin Immunol 43:850–873CrossRef
138.
139.
Wark PA, Hensley MJ, Saltos N et al (2003) Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 111:952–957PubMedCrossRef
140.
Moss RB (2012) The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis. Ann N Y Acad Sci 1272:49–57PubMedCrossRef
141.
Zirbes JM, Milla CE (2008) Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 43:607–610PubMedCrossRef
142.
Gupta D (2011) Allergic Bronchopulmonary Aspergillosis (ABPA): Relevance of Absolute Eosinophil Count (AEC) in Peripheral Blood. Chest 140
143.
Denning DW, O’Driscoll BR, Hogaboam CM, Bowyer P, Niven RM (2006) The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 27:615–626PubMedCrossRef
144.
Denning DW, O’Driscoll BR, Powell G et al (2009) Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 179:11–18PubMedCrossRef
145.
Klion AD, Nutman TB (2004) The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol 113:30–37PubMedCrossRef
146.
147.
148.
149.
Pandit R, Scholnik A, Wulfekuhler L, Dimitrov N (2007) Non-small-cell lung cancer associated with excessive eosinophilia and secretion of interleukin-5 as a paraneoplastic syndrome. Am J Hematol 82:234–237PubMedCrossRef
150.
Slungaard A, Ascensao J, Zanjani E, Jacob HS (1983) Pulmonary carcinoma with eosinophilia. Demonstration of a tumor-derived eosinophilopoietic factor. N Engl J Med 309:778–781PubMedCrossRef
151.
Wilson F, Tefferi A (2005) Acute lymphocytic leukemia with eosinophilia: two case reports and a literature review. Leukemia & Lymphoma 46:1045–1050CrossRef
152.
Furuta K, Taki M, Murase H, Nakagawa A, Nishiyama H, Nohgawa M (2011) [A case of eosinophilic pneumonia which occurred after bone marrow transplantation for acute myeloid leukemia]. Journal of the. Jpn Respir Soc 49:20–24
153.
Trojan A, Meier R, Licht A, Taverna C (2002) Eosinophilic pneumonia after administration of fludarabine for the treatment of non-Hodgkin’s lymphoma. Ann Hematol 81:535–537PubMedCrossRef
154.
Verstraeten AS, De Weerdt A, van Den Eynden G, Van Marck E, Snoeckx A, Jorens PG (2011) Excessive eosinophilia as paraneoplastic syndrome in a patient with non-small-cell lung carcinoma: a case report and review of the literature. Acta Clin Belg 66:293–297PubMed
155.
Stevens DA, Moss RB, Kurup VP et al (2003) Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: cystic fibrosis foundation consensus conference. Clin Infect Dis Off Publ Infect Dis Soc Am 37(Suppl 3):S225–S264CrossRef
Metadata
Title
The Role and Immunobiology of Eosinophils in the Respiratory System: a Comprehensive Review
Authors
Stephanie S. Eng
Magee L. DeFelice
Publication date
01-04-2016
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 2/2016
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-015-8526-3

Other articles of this Issue 2/2016

Clinical Reviews in Allergy & Immunology 2/2016 Go to the issue

ReviewPaper

Hypereosinophilic Syndrome

ReviewPaper

Biological Modulators in Eosinophilic Diseases

ReviewPaper

Eosinophilic Skin Diseases: A Comprehensive Review

ReviewPaper

Medical Complications of Tattoos: A Comprehensive Review

OriginalPaper

Eosinophilic Drug Allergy

ReviewPaper

Eosinophilic Esophagitis: A Comprehensive Review
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits